Pan-genotypic regimen for HCV effective in eight weeks for the majority of patients1
1. Puoti M. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293-300
Product profile
Maviret (glecaprevir/pibrentasvir) combines two new potent antiviral agents with in vitro activity against the six major genotypes of HCV and a high barrier to the selection of the most common variants associated with resistance.
Maviret: fixed-dose combination, targeted at multiple phases of the HCV life cycle1,4
The potent in vitro activity of glecaprevir and pibrentasvir is translated into great clinical effectiveness1,2
in Phase 2/3 studies on 2,256 patients with Gt1-6 with a treatment duration of 8, 12 and 16 weeks, independent of the patient's viral characteristics
* mITT, modified intention to treat excludes non-virologic failures. The data includes treatment-naïve patients or those previously treated with peg-IFN + ribavirin +/- sofosbuvir or sofosbuvir + ribavirin, with or without compensated cirrhosis2
Reference the most recent version of the SmPC, scanning the QR Code.
The continually updated version of the SmPC is also available on the website https://rcpabbvie.it/mav
Ex-factory price (VAT EXCLUDED): € 14,000
Retail price (VAT EXCLUDED): € 23,105.60
Reimbursement class: A
Classification for supply: medicinal products subject to limited medical prescription, with single refills, sold to the public by prescription from hospital centers or specialists: infectious disease specialists, gastroenterologists, internists (RNRL)
Stored at AIFA on 09/25/2019 - Code IT-MAVI-190076
Translated from the Italian local content. Global approved content coming soon.
Bibliografia:
1. MAVIRET, Riassunto delle Caratteristiche
di Prodotto
2. Ng TI, et al. “In Vitro Antiviral Activity and
Resistance Profile of the Next Generation Hepatitis C Virus NS3/4A
Protease Inhibitor Glecaprevir.” Antimicrob Agents Chemother. 2017 Oct
30.
3. Ng TI, et al. “In Vitro Antiviral Activity and Resistance
Profile of the Next Generation Hepatitis C Virus NS5A Inhibitor
Pibrentasvir.” Antimicrob Agents Chemother. 2017 Apr 24;61(5)